1004316-88-4 | 1,3-thiazol-5-ylmethyl N-[(2R,5R)-5-[(2S)-2-{[methyl({[2-(propan-2-yl)-1,3-thiazol-4-yl]methyl})carbamoyl]amino}-4-(morpholin-4-yl)butanamido]-1,6-diphenylhexan-2-yl]carbamate

Packsize	Purity	Availability	Price	Discounted Price
1mg	≥98%	in stock	$48.00	$34.00
5mg	98%	in stock	$127.00	$89.00
25mg	98%	in stock	$322.00	$226.00
100mg	98%	in stock	$856.00	$599.00

Description

• Catalog Number: AA02367
• Chemical Name: 1,3-thiazol-5-ylmethyl N-[(2R,5R)-5-[(2S)-2-{[methyl({[2-(propan-2-yl)-1,3-thiazol-4-yl]methyl})carbamoyl]amino}-4-(morpholin-4-yl)butanamido]-1,6-diphenylhexan-2-yl]carbamate
• CAS Number: 1004316-88-4
• Molecular Formula: C40H53N7O5S2
• Molecular Weight: 776.0227
• MDL Number: MFCD18251449
• SMILES: O=C(N[C@@H](Cc1ccccc1)CC[C@H](Cc1ccccc1)NC(=O)[C@@H](NC(=O)N(Cc1csc(n1)C(C)C)C)CCN1CCOCC1)OCc1cncs1

Computed Properties

• Complexity: 1120
• Covalently-Bonded Unit Count: 1
• Defined Atom Stereocenter Count: 3
• Heavy Atom Count: 54
• Hydrogen Bond Acceptor Count: 10
• Hydrogen Bond Donor Count: 3
• Rotatable Bond Count: 20
• XLogP3: 5.7

Literature

• Pharmacokinetic enhancers in HIV therapeutics.

  Clinical pharmacokinetics 20141001

• Cobicistat boosts the intestinal absorption of transport substrates, including HIV protease inhibitors and GS-7340, in vitro.

  Antimicrobial agents and chemotherapy 20121001

• Effect of cobicistat on glomerular filtration rate in subjects with normal and impaired renal function.

  Journal of acquired immune deficiency syndromes (1999) 20120901

• Combinational therapies for HIV: a focus on EVG/COBI/FTC/TDF.

  Expert opinion on pharmacotherapy 20120901

• [A single tablet against HIV: new combination preparation improves therapy].

  Deutsche medizinische Wochenschrift (1946) 20120801

• Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate versus ritonavir-boosted atazanavir plus co-formulated emtricitabine and tenofovir disoproxil fumarate for initial treatment of HIV-1 infection: a randomised, double-blind, phase 3, non-inferiority trial.

  Lancet (London, England) 20120630

• Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus co-formulated efavirenz, emtricitabine, and tenofovir for initial treatment of HIV-1 infection: a randomised, double-blind, phase 3 trial, analysis of results after 48 weeks.

  Lancet (London, England) 20120630

• Phase 2 study of cobicistat versus ritonavir each with once-daily atazanavir and fixed-dose emtricitabine/tenofovir df in the initial treatment of HIV infection.

  AIDS (London, England) 20110924

• Randomized, phase 2 evaluation of two single-tablet regimens elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate versus efavirenz/emtricitabine/tenofovir disoproxil fumarate for the initial treatment of HIV infection.

  AIDS (London, England) 20110327

• Pharmacokinetics and bioavailability of an integrase and novel pharmacoenhancer-containing single-tablet fixed-dose combination regimen for the treatment of HIV.

  Journal of acquired immune deficiency syndromes (1999) 20101101

• Cobicistat (GS-9350): A Potent and Selective Inhibitor of Human CYP3A as a Novel Pharmacoenhancer.

  ACS medicinal chemistry letters 20100812

• Pharmacokinetics and pharmacodynamics of GS-9350: a novel pharmacokinetic enhancer without anti-HIV activity.

  Clinical pharmacology and therapeutics 20100301